CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

ombitasvir/paritaprevir/ritonavir and dasabuvir

Last Updated: January 6, 2016
Result type: Reports
Project Number: SF0466-000
Product Line: Reimbursement Review

Generic Name: ombitasvir/paritaprevir/ritonavir and dasabuvir

Brand Name: Holkira Pak

Manufacturer: AbbVie Corporation

Therapeutic Area: Hepatitis C, chronic

Indications: Hepatitis C, chronic

Submission Type: Request For Advice

Project Status: Complete

Date Recommendation Issued: May 19, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions